Taysha Gene Therapies, Inc. TSHA Balance Sheet Statement
| TTM Q1 '26 | TTM Q4 '25 | TTM Q3 '25 | TTM Q2 '25 | TTM Q1 '25 | ||
|---|---|---|---|---|---|---|
| $276.58M-13.5% | $319.77M+7.5% | $297.34M-4.9% | $312.76M+168% | $116.59M-16.1% | ||
| $449K0.0% | $449K0.0% | $449K0.0% | $449K0.0% | $449K0.0% | ||
| $14.87M+11.7% | $13.31M+15.5% | $11.52M-9.9% | $12.78M-1.7% | $13.01M-3.7% | ||
| —— | —— | —— | —— | —— | ||
| $282.25M-13.1% | $324.65M+8.2% | $299.95M-5.2% | $316.26M+162% | $120.71M-15.1% | ||
| $6.45M-4.2% | $6.74M-1.0% | $6.81M-2.2% | $6.96M-3.9% | $7.24M-3.3% | ||
| $9.16M-3.0% | $9.44M+26.5% | $7.46M-4.0% | $7.77M-3.8% | $8.08M-3.6% | ||
| $181K-1.1% | $183K-0.5% | $184K-1.1% | $186K-1.1% | $188K-13.4% | ||
| $300.35M-12.5% | $343.32M+8.5% | $316.55M-5.0% | $333.33M+141% | $138.36M-13.7% | ||
| $23.99M+1.0% | $23.75M+12.7% | $21.07M+2.5% | $20.56M-4.7% | $21.57M-21.9% | ||
| $15.53M-23.4% | $20.28M+14.5% | $17.71M+45.7% | $12.15M+12.9% | $10.76M-16.3% | ||
| —— | —— | $5.49M0.0% | $5.49M-26.6% | $7.47M-23.6% | ||
| $1.55M+4.2% | $1.49M+19.4% | $1.25M-6.1% | $1.33M-5.7% | $1.41M-5.4% | ||
| $275K-27.4% | $379K-10.4% | $423K+2.7% | $412K+2.5% | $402K+2.8% | ||
| $20.1M-24.3% | $26.55M-7.3% | $28.63M+12.9% | $25.35M+12.4% | $22.56M-14.0% | ||
| $48.96M-2.3% | $50.11M-1.5% | $50.85M+23.9% | $41.05M-3.3% | $42.45M-3.4% | ||
| $17.77M-2.2% | $18.17M+10.1% | $16.51M-1.8% | $16.81M-1.7% | $17.09M-1.5% | ||
| $275K-27.4% | $379K-21.0% | $480K-17.1% | $579K-14.5% | $677K-12.1% | ||
| $19.32M-1.7% | $19.66M+10.7% | $17.75M-2.1% | $18.13M-2.0% | $18.5M-1.8% | ||
| $1.58M+1.9% | $1.55M-1.5% | $1.58M+12.9% | $1.4M+16.3% | $1.2M-8.3% | ||
| $88.41M-8.3% | $96.38M-1.2% | $97.57M+15.3% | $84.6M+1.6% | $83.3M-6.2% | ||
| $3K0.0% | $3K0.0% | $3K0.0% | $3K+50.0% | $2K0.0% | ||
| $964.67M+0.7% | $958.43M+6.1% | $903.58M+0.4% | $900.14M+32.1% | $681.18M+0.5% | ||
| -$753.71M-6.0% | -$711.3M-4.1% | -$683.45M-5.0% | -$650.72M-4.3% | -$623.83M-3.6% | ||
| $985K+613% | -$192K+83.2% | -$1.14M-63.5% | -$699K+69.4% | -$2.29M+43.3% | ||
| $211.94M-14.2% | $246.94M+12.8% | $218.99M-12.0% | $248.73M+352% | $55.06M-23.0% | ||
| $300.35M-12.5% | $343.32M+8.5% | $316.55M-5.0% | $333.33M+141% | $138.36M-13.7% | ||
| $181K-1.1% | $183K-0.5% | $184K-1.1% | $186K-1.1% | $188K-13.4% | ||
| $9.16M-3.0% | $9.44M+26.5% | $7.46M-4.0% | $7.77M-3.8% | $8.08M-3.6% | ||
| $9.16M-3.0% | $9.44M+26.5% | $7.46M-4.0% | $7.77M-3.8% | $8.08M-3.6% | ||
| $181K-1.1% | $183K-0.5% | $184K-1.1% | $186K-1.1% | $188K-13.4% | ||
| $9.16M-3.0% | $9.44M+26.5% | $7.46M-4.0% | $7.77M-3.8% | $8.08M-3.6% | ||
| $181K-1.1% | $183K-0.5% | $184K-1.1% | $186K-1.1% | $188K-13.4% | ||
| $15.53M-23.4% | $20.28M+14.5% | $17.71M+45.7% | $12.15M+12.9% | $10.76M-16.3% | ||
| $68.55M-2.3% | $70.14M+1.5% | $69.08M+15.6% | $59.76M-3.0% | $61.63M-3.0% | ||
| $3K0.0% | $3K0.0% | $3K0.0% | $3K+50.0% | $2K0.0% | ||
| $275K-27.4% | $379K-10.4% | $423K+2.7% | $412K+2.5% | $402K+2.8% |
Chart any of these lines over time, or line them up against competitors.
Compare these in charts →Questions, answered.
- What are Taysha Gene Therapies, Inc.'s total assets?
- Taysha Gene Therapies, Inc. (TSHA) holds $300.4M in total assets, up 117.1% year over year.
- How much debt does Taysha Gene Therapies, Inc. have?
- Taysha Gene Therapies, Inc. carries $68.6M in total debt against $211.9M of shareholders' equity, a debt-to-equity ratio of 0.32.
- How much cash does Taysha Gene Therapies, Inc. have?
- Taysha Gene Therapies, Inc. holds $276.6M in cash and equivalents.
- Can Taysha Gene Therapies, Inc. cover its short-term obligations?
- Its current ratio is 14.04 — current assets exceed current liabilities.
- Where does Taysha Gene Therapies, Inc.'s balance sheet data come from?
- Every line is extracted from Taysha Gene Therapies, Inc.'s SEC filings (10-K and 10-Q) and tagged in XBRL. Switch between quarterly, annual, and trailing-twelve-month views, or open any line for its full history and peer comparisons.
